PON1 and rheumatoid arthritis: HDL dysfunction has been linked to CV events in the general population [10], and we recently demonstrated an association of impaired HDL function measured by suppressed PON1 activity with the risk of CV events in a large RA developmental program of the RA therapeutic, tofacitinib [18].